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Hereditary angioedema is an autosomal dominant disease characterized by edema attacks with multiple organ
involvement. It is caused by a quantitative or functional deficiency of the C1 inhibitor, which is a member of the
serine protease inhibitor family. Hereditary angioedema is unknown to many health professionals and is therefore
an underdiagnosed disease. The causes of death from hereditary angioedema include laryngeal edema with
asphyxia. The estimated mortality rate in patients in whom the disease goes undetected and who are therefore
incorrectly treated is 25-40%. In addition to edema of the glottis, hereditary angioedema often results in edema of
the gastrointestinal tract, which can be incapacitating. Patients with hereditary angioedema may undergo
unnecessary surgical interventions because the digestive tract can be the primary or only organ system involved,
thus mimicking acute surgical abdomen. It is estimated that patients with hereditary angioedema experience some
degree of disability 20-100 days per year. The Experts in Clinical Immunology and Allergy of the ‘‘Associac ¸a ˜o
Brasileira de Alergia e Imunopatologia - ASBAI’’ developed these guidelines for the diagnosis, therapy, and
management of hereditary angioedema.
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DEFINITION
What is hereditary angioedema?
Hereditary angioedema (HAE) is an autosomal dominant
disease that is characterized by edema attacks with multiple
organ involvement. It is caused by quantitative or functional
deficiency of the C1 inhibitor (C1-INH), which is a member
of the serine protease inhibitor family.
INTRODUCTION
Why should we study HAE?
HAE was first described as a clinical entity by Quincke in
1882, and its hereditary nature was established by Osler in
1888.
1,2 The biochemical change associated with HAE, C1-
INH deficiency, was not identified until 75 years later, in
1963.
3
Sir William Osler (1849-1919), a Canadian physician who
lived in the United States and England, was renowned for
his many contributions to medicine, including his participa-
tion in the description of HAE and for stating that
‘‘Medicine is both a Science and an Art’’. To develop
evidence-based guidelines is to practice medicine as a
science. To follow such guidelines and consensuses while
treating patients and their various phenotypes in a
personalized manner is to practice medicine as an art.
HAE is a disease that is unknown to many health
professionals and is therefore underdiagnosed. The pre-
valence of HAE is approximately 1550,000 (with estimates
ranging from 1510,000 to 15150,000); the disease affects
various ethnic groups and accounts for 2% of all cases of
angioedema.
4-7
As is true for other autosomal dominant diseases, the
children of a patient with HAE have a 50% chance of
carrying the anomalous gene. Although a family history is
characteristic of the disease and should alert physicians to a
possible diagnosis of HAE, in 20-25% of cases, a family
history of disease is absent, and new, spontaneous muta-
tions can be observed.
8 Approximately 200 HAE-associated
mutations have been identified to date. Although genetic
defects are found in patients of both genders with equal
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1627frequency, the phenotype is more common in female
patients, for whom the disease is more severe.
9
The time elapsed between the onset of symptoms and
diagnosis, as well as the time between diagnosis and the
initiation of treatment, play important roles in HAE-related
morbidity and mortality.
10-13 Therefore, physicians should
be aware of the clinical profile and laboratory tests that
confirm a diagnosis of HAE and inform decisions regarding
its treatment.
The cause of death from HAE is laryngeal edema with
asphyxia, and the estimated mortality rate in patients in
whom the disease goes undetected and who are therefore
incorrectly treated is 25-40%.
7,10-15 Patients with HAE are
commonly hospitalized and admitted to intensive care
units, and the disease accounts for 15,000-30,000 emergency
room visits per year in the United States.
16
The two most severe clinical manifestations of HAE are
edema of the larynx and edema of the bowel wall. Delayed
diagnosis increases morbidity, thereby affecting the quality
of life of patients and their families.
17,18 A study involving
two families showed that nine out of ten family members
who were hospitalized for symptoms of HAE were
discharged with diagnoses other than HAE.
19
In addition to life-threatening edema of the glottis, HAE
often results in edema of the gastrointestinal tract, which
can be incapacitating. Patients with HAE may undergo
unnecessary surgical interventions because the digestive
tract can be the primary or only organ system involved, thus
mimicking acute surgical abdomen.
20,21 It is estimated that
patients with HAE experience some degree of disability 20-
100 days per year.
17
PATHOPHYSIOLOGY
What is the cause of HAE?
Patients with HAE present with a quantitative or
qualitative deficiency of C1-INH, which is a serine protease
inhibitor. This enzyme inhibits the C1r and C1s esterases,
which bind to and activate C1q. Without such inhibition, the
complement system becomes excessively activated.
22,23
C1-INH also inhibits the lectin pathway of complement
system activation and participates in the regulation of the
contact, coagulation, and fibrinolysis systems. Deficiency of
C1-INH results in increased bradykinin production.
Episodes of angioedema were initially attributed to factors
that were formed during complement system activation,
including a C2 fragment (C2 kinin) that is associated with
vasodilation and increased vascular permeability.
24 Recent
evidence has shown that bradykinin is one of the principal
mediators of HAE.
25-27
It has been shown that bradykinin levels are higher in
blood drawn from angioedematoussites than in blooddrawn
from the systemic circulation.
25 Knockout mice with con-
comitant deficiencies of C1-INH and bradykinin receptor B2
(BDKRB2) display decreased vascular permeability, which
demonstrates that the bradykinin/BDKRB2 pathway plays
an important role in the development of angioedema.
26
CLASSIFICATION
What are the types of HAE?
Currently, HAE is divided into three groups (Table 1).
Most patients (80-85%) present with type I HAE, with
reduced C1-INH synthesis (a quantitative defect).
28 Low
serum levels of C1-INH trigger the attacks.
In patients who present with type II HAE (15-20%),
adequate quantities of C1-INH are produced, although the
functional capacity of the protein is partially diminished.
29
Therefore, the enzyme has a qualitative (i.e., functional)
defect.
Type III HAE is rarer than types I and II and principally
affects females. It is characterized by normal C1-INH levels
and activity.
30 This group includes diseases that vary in
their etiopathogenesis; coagulation disorders and links to
the endocrine system have been identified in this
group.
9,31,32
Acquired angioedema (AAE), which has a manifestation
similar to that of HAE, is noteworthy among the differential
diagnoses of HAE.
33 AAE is characteristically associated
with lymphoproliferative and autoimmune diseases in
which there is consumption of C1-INH, which is caused
by the activation of C1-INH or by the production of anti-C1-
INH autoantibodies.
34
DIAGNOSIS
What is the typical clinical manifestation of HAE?
The patient’s clinical history is the principal component of
an HAE diagnosis. Patients with HAE present with attacks
of nonpruritic edema of the skin and submucosa that affects
various organs.
11-13 The most commonly affected sites are
the face, extremities, genitalia, oropharynx, larynx, and
digestive system. However, rarer clinical manifestations,
including intense headaches caused by brain edema,
urinary retention, and acute pancreatitis, can also occur.
12,35
The incidence and severity of the clinical manifestations
of HAE vary among individuals. It has been reported that
5% of patients with HAE are asymptomatic, and 25%
develop sporadic symptoms.
6,11,12,36-38 A retrospective
study analyzing 131,110 attacks in 221 patients with HAE
reported that laryngeal edema occurred in less than 1%
of the attacks, although over 50% of the patients had
previously experienced that symptom at least once.
12
Left untreated, HAE attacks typically last 48-72 h.
Although many attacks occur spontaneously, a number of
triggering factors have been identified, including minor
trauma, stress, infection, menstruation, pregnancy, alcohol
consumption, a change in temperature, exercise, the use of
angiotensin-converting enzyme (ACE) inhibitors, and the
use of estrogen (including contraceptives and hormone
replacement therapy).
6,11,12,36-39
Serpiginous erythema can occur as a prodromal manifes-
tation that precedes angioedema in some patients; however,
the concomitant presence of pruritic urticaria makes the
diagnosis of HAE unlikely.
6,11,12,36-38 However, some cases
of HAE coexisting with urticaria have been reported.
40
A family history of clinical manifestations that are similar
to those seen in the patient supports a diagnosis of HAE,
although this type of family history is absent in approxi-
mately 25% of cases.
8
In children, the clinical manifestations of HAE generally
develop before six years of age. However, the onset of
clinical manifestations in infants is rare, and few cases have
been described. Attacks of laryngeal edema are particularly
rare before three years of age and tend to occur later than
other manifestations. During adolescence, there are sub-
stantial changes in disease activity, particularly in girls, for
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1628whom disease progression is worse because of their
menstrual cycles and their use of contraceptives containing
estrogen.
6,11,12,36-38
Although the manifestations of type III HAE are similar to
those of the other HAE types, there are certain features
unique to this type. Symptom onset generally occurs later in
life, the course of the disease tends to be more benign, and
tongue involvement is common. Purpura is occasionally
seen at sites that are affected by angioedema. However, the
most striking characteristic of type III HAE is a personal and
family history of associations between the disease and
female gender and between the disease and estrogen
administration.
In AAE, the onset of symptoms also occurs later, there is
no family history of angioedema, and the associations
between AAE and lymphoproliferative diseases and
between AAE and autoimmune diseases should be inves-
tigated.
33,34
How can laboratory tests confirm the diagnosis of
HAE?
Individuals who are clinically suspected of having HAE
and individuals with a family history of HAE should be
investigated (Table 2). The principal screening test is the
determination of serum levels of C4.
6,36-38
Quantitative or qualitative C1-INH deficiency leads to the
permanent activation of the complement system, accom-
panied by C4 consumption, even when patients are not
experiencing an angioedema attack. In 2-5% of cases, C4
levels normalize during the intercrisis period.
41
C3 turnover is greater than C4 turnover. In addition, there
are other proteins that, together with C1-INH, regulate the
consumption of C3, the levels of which are generally normal
in HAE patients. Therefore, the determination of C3 levels is
unnecessary except in patients who are suspected of having
AAE, principally in the presence of autoimmune dis-
eases.
6,36-38 In AAE, there is activation and consumption of
complement components, and 75% of patients present with
reduced serum levels of C1q.
42 Therefore, the determination
of C1q levels can aid in the differentiation between HAE
and AAE.
Following (or concomitant with) the determination of
serum levels of C4, quantitative and qualitative determina-
tions of C1-INH should be performed. All health profes-
sionals and family members who are involved in providing
care for patients with HAE must ensure that such tests are
available. Although the quantitative determination of C1-
INH is a relatively easy test to perform, the determination of
functional enzymatic activity (qualitative test) should be
performed at a referral laboratory.
6,36-38 Importantly, the
determination of functional activity is only necessary when
C1-INH levels are normal (Figure 1).
If clinical suspicion remains despite normal C4 levels
and normal (quantitative/qualitative) C1-INH levels, these
tests should be performed again during an angioedema
attack.
6,36-38 If the test results are again normal, a diagnosis
of type III HAE is suggested.
30
What are the diagnostic criteria for HAE?
Criteria to standardize the diagnosis of HAE have been
proposed (Table 3).
36 According to these criteria, the
presence of HAE is confirmed when patients meet one
major clinical criterion and one biochemical criterion.
It should be noted that those criteria are not absolute and
that the patient’s clinical history takes precedence, princi-
pally in locations where the laboratory tests are not
available and in suspected cases of type III HAE. In selected
cases, we can presume a diagnosis of HAE and perform a
therapeutic test.
TREATMENT
Guidance
To improve the quality of life of patients and their
families and to avoid severe complications, the most
important initial measure is to provide guidance regarding
the course of HAE and the triggering factors for attacks.
Patients should be given relevant information (in writing)
regarding the disease and the steps that must be taken in the
case of an attack (an action plan). There are nonpharmaco-
logical approaches that can reduce HAE severity and
therefore merit attention.
Table 1 - Classification of hereditary angioedema.
TYPE DEFECT
Type I – Quantitative Decreased C1 inhibitor synthesis
Type II - Functional; Qualitative Decreased C1 inhibitor function
Type III Normal C1 inhibitor levels and function
A- Estrogen-dependent or estrogen-related
B- Mutation of factor XII (Hageman factor)
C- Idiopathic
Table 2 - Laboratory diagnosis of angioedema.
Type of Angioedema C1-INH level C1-INH function C4 C3 C1q
Type I HAE Low Low Low Normal Normal
Type II HAE Normal Low Low Normal Normal
Type III HAE Normal Normal Normal Normal Normal
AAE Low Low Low Normal/Low Low
ACE inhibitor Normal Normal Normal Normal Normal
Idiopathic Normal Normal Normal Normal Normal
C1-INH: C1 inhibitor, HAE: hereditary angioedema, AAE: acquired angioedema, ACE: angiotensin-converting enzyme.
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1629Because of the significant morbidity and mortality
associated with HAE, a strategy involving careful treatment
and prevention of attacks is essential for appropriate patient
management (Table 4). The experience at large centers has
demonstrated that 25-40% of patients can develop asphyxia
and die if they are left untreated.
7,10-15
Prevention of attacks
The risk of attacks can be reduced by identifying and
eliminating the factors that trigger them. Stress and trauma
are clearly triggering factors for edema in HAE, so patients
should monitor those factors. High-impact sports and
hobbies that pose a risk of trauma should be avoided. To
prevent infections, which constitute a trigger of attacks,
immunization is indicated. Hepatitis B vaccination is
recommended because blood products might be used
during the treatment of HAE attacks.
43
Drugs that can worsen or prolong an HAE attack
The drugs that most commonly worsen or prolong the
clinical profile of HAE or AAE are ACE inhibitors,
angiotensin II receptor antagonists, medications containing
estrogen, and certain oral hypoglycemic agents.
Because ACE inhibitors increase the half-life of bradyki-
nin, their use should be avoided.
44 Angiotensin II receptor
antagonists can also worsen the clinical profile of HAE,
although they do so less commonly than ACE inhibitors.
45
Contraceptives containing progesterone should be pre-
ferentially prescribed over those containing estrogen.
16,46
Sitagliptin phosphate, which is an oral hypoglycemic
agent indicated for the treatment of type 2 diabetes, belongs
to a class of oral hypoglycemic agents designated dipeptidyl
peptidase-4 inhibitors, which can worsen the clinical profile
of HAE.
47
Genetic screening of family members
All first-degree relatives of patients with HAE should be
screened for HAE. In pediatric patients with a family history
of HAE, the HAE diagnostic tests should be performed at
six months of age and repeated at one year.
48
Patients and their families should receive genetic counsel-
ing and guidance regarding the inheritance pattern of the
disease.
49
Pharmacological treatment
The pharmacological treatment of HAE can be divided
into three modalities: long-term prophylaxis, short-term
prophylaxis, and treatment of attacks.
The therapies recommended here were classified accord-
ing to the strength of the recommendation, which is based
on the level of scientific evidence supporting such a
recommendation (Table 5).
How should long-term prophylaxis be performed?
The objective of long-term prophylaxis in HAE is to
reduce the frequency and severity of attacks. These two
variables can vary widely. Patients may be asymptomatic or
experience attacks twice per week with symptoms that are
practically continuous. Therefore, the first question regard-
ing long-term prophylaxis should be whether patients
actually require this type of treatment.
In general, individuals with frequent symptoms or a
history of angioedema attacks involving the upper airways
should be treated prophylactically. Patients who are
candidates for this type of treatment are those who present
with more than one severe attack per month or those who
experience more than five attacks per month.
6,36-38
Although the number and severity of angioedema attacks
play important roles in this evaluation, the impact of
angioedema episodes on the patient’s quality of life is a
decisive aspect. Another important point to be considered is
whether patients have access to appropriate medical care in
the case of a severe episode of angioedema.
50
In Brazil, two treatment modalities are available for long-
term prophylaxis: attenuated androgens and antifibrinolytic
agents.
The most effective and best tolerated therapy for long-
term prophylaxis of HAE is attenuated androgens that
increase the levels of C1-INH and C4 and reduce the
number of attacks of angioedema (grade B recommenda-
tion).
51 The drugs used include danazol, stanozolol, and
oxandrolone, which are less virilizing than methyltestoster-
one. Oxandrolone is especially recommended for use in
children.
52
Table 3 - Diagnostic criteria for hereditary angioedema.
36
I-Primary clinical criteria
a) Non-inflammatory subcutaneous angioedema
lasting longer than 12 h
b) Abdominal pain of undefined organic etiology lasting longer than 6 h
c) Recurrent laryngeal edema
II - Secondary clinical criteria
a) Family history of hereditary angioedema
III - Biochemical criteria
a) Quantitative C1 inhibitor ,50% in two distinct samples
b) Functional C1 inhibitor ,50% in two distinct samples
c) Mutation in the C1 inhibitor gene
Figure 1 - Diagnostic algorithm of hereditary angioedema. C1-
INH: C1 inhibitor, HAE: hereditary angioedema, AAE: acquired
angioedema, NL: normal.
Table 4 - General recommendations for the medical
treatment of attacks of hereditary angioedema.
Take a personal and family history of the acute attack profile
Use oxygenation and pulse oximetry
Hydrate
Use antispasmodics and analgesics as needed
Avoid the use of angiotensin-converting enzyme inhibitors
Increase the dose of chronic medication to control the attack
Use acute phase control agents (fresh plasma, C1 inhibitor, bradykinin
receptor antagonist, or kallikrein inhibitor) if available
Hereditary angioedema guidelines
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1630In Brazil, the most widely used attenuated androgen is
danazol, which is also the most widely available (its
availability is guaranteed by the High-Cost Drug
Program); in addition, well-controlled studies have demon-
strated the clinical efficacy of this drug and have shown that
it improves biochemical parameters.
51,53,54
Treatment with danazol can be started at high doses (600
mg/day), which can later be reduced. Another option is to
start at a low dose (50-200 mg) and increase the dose as
needed. Therefore, two protocols have been established:
6
a) Milan Protocol—Initiation at a high dose with a
subsequent reduction:
- 400-600 mg/day of danazol for one month
- Wean by 1/3, or 100 mg, every month
- At 200 mg/day, taper by 50 mg every two months
- At 100 mg/day, taper by 50 mg every three months
- Minimum dose of 50 mg/day, five days per week
- If the symptoms recur, re-induce remission with the
initial dose and wean to a higher maintenance dose
than the previously administered dose.
b) Budapest Protocol—Initiation at a low dose with a
subsequent increase:
- 2.5 mg/kg of danazol (maximum of 200 mg) admi-
nistered daily for one month
- If there is no response, increase to 300 mg/day for
two-four weeks
- If there is no response, increase to 400 mg/day for
two-four weeks
- If controlled at 200 mg, reduce to 100 mg/day for
one month
- If controlled at 100 mg, reduce to 50 mg/day or
100 mg on alternate days
- If there are prodromal symptoms of attack, double
the dose for several days.
The best strategy should be chosen based on the patient’s
clinical status. Therefore, we should consider whether it is
more important to control the angioedema attacks as fast as
possible or to minimize the potential adverse effects of the
drug. In both protocols, the final dose should be the lowest
dose that provides adequate prophylaxis, generally ranging
from the administration of 50 to 200 mg/day or on alternate
days.
Although androgens increase the levels of C1-INH and
C4, symptomatic benefits are generally achieved at doses
lower than those required to significantly alter the levels of
complement components. Therefore, it is important that the
drug dosage is based on the patient’s clinical symptoms
rather than his or her biochemical parameters. It should be
emphasized that androgens are ineffective in controlling
attacks of HAE because it takes approximately 48 h for the
drugs to begin to take effect.
55
Most patients tolerate androgens at the aforementioned
doses. However, sustained use at higher doses generally
results in significant adverse effects. The adverse effects of
androgens are related to the dosage, with the major adverse
effects being hepatotoxicity and virilization.
56
Other adverse reactions include weight gain, headache,
menstrual changes, acne, changes in libido, anxiety, mood
disorders, hypertension, myopathy, changes in lipid pro-
files, and hematuria.
57 Although there is evidence of
changes in patients’ lipid profiles, the association between
danazol and atherosclerosis is controversial.
57-59 Danazol-
induced hematuria results from mild cystitis or bladder
telangiectasia.
60 These adverse effects tend to disappear
after the discontinuation of the drug.
In individuals receiving androgens, the hepatic enzyme
levels should be evaluated every six months. If liver damage
develops, the dose should be reduced or the drug should be
discontinued until these tests yield normal results.
Because hepatic adenomas and hepatocellular carcinoma
have previously been reported as consequences of the use of
androgens, liver ultrasounds should also be routinely
performed every six months.
61,62 The development of liver
tumors in patients who are using danazol has been
associated with the use of higher doses (400-800 mg), a
longer duration of administration, and the lack of monitor-
ing for liver injury.
63
Although many patients complain of androgen-induced
adverse events, most patients with HAE can benefit, at least
moderately, from androgen use, and the risk profile is
acceptable.
Danazol is contraindicated during pregnancy because
there have been documented cases of virilization in female
neonates. However, discontinuation of the drug by gesta-
tional week eight has been shown to avert that alteration.
64-66
Other contraindications for danazol use include breastfeed-
ing and prostate cancer, as well as kidney, liver, and heart
failure.
Table 5 - Evidence levels and degrees of recommendation
for therapies.
Levels of evidence
Level Meaning
1 One or more randomized controlled clinical trials of sufficient
sample size with a narrow confidence interval
Meta-analysis of randomized controlled clinical trials
2 Good quality cohort study
Low-quality randomized clinical trial (small sample size and
.20% lost to follow-up)
3 Case-control studies
Meta-analysis of case-control studies
4 Case series
Low-quality cohort studies
Low-quality case-control studies
5 Based on expert opinions, experimental studies or physiology
Grade/Strength of recommendation
Grade Meaning
A Corresponding to level of evidence 1
B Corresponding to level of evidence 2 or 3
Extrapolated from level 1 studies involving populations other
than the current population
C Corresponding to level of evidence 4
Extrapolated from level 2 or 3 studies involving populations
other than the current population
D Corresponding to level of evidence 5
Adapted from: Levels of evidence and grades of recommendation, Oxford
Center for Evidence-Based Medicine, May 2001.
http://www.cebm.net/levels_of_evidence.
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1631Antifibrinolytic agents (epsilon-aminocaproic acid and
tranexamic acid) are generally effective (grade B recom-
mendation) in preventing HAE attacks.
67-71 These drugs
antagonize the fibrinolytic system by blocking plasmin
formation and inhibiting the proteolytic activity of plasmi-
nogen activators and, consequently, clot dissolution. The
mechanism by which antifibrinolytic agents prevent HAE
attacks remains unknown. Unlike attenuated androgens,
antifibrinolytic agents do not increase the serum levels of
C1-INH or C4.
The therapeutic dose of epsilon-aminocaproic acid is 1 g,
administered orally three to four times per day, and it can
be as high as 8 g/day.
55 Tranexamic acid should be
administered at a dose of 0.5-0.75 mg/kg two to three times
per day; the drug is more potent than aminocaproic acid
and has a lower incidence of adverse effects.
72 The side
effects of antifibrinolytic agents include nausea, diarrhea,
vertigo, postural hypotension, fatigue, muscle weakness,
cramps, and increased muscle enzyme levels.
50 Other
adverse effects that are associated with the inhibition of
plasmin include the increased occurrence of thrombosis and
increased tumor growth. Because of the risks of teratogeni-
city, the use of antifibrinolytic agents during pregnancy is
restricted.
50
As occurs with attenuated androgens, the time of onset of
the therapeutic effects of antifibrinolytic agents is approxi-
mately 48 h after administration. Therefore, both classes of
drugs are of little use in providing immediate symptom
relief. Because anabolic androgens are more effective in
controlling HAE, they generally constitute the treatment of
choice (grade C recommendation). Antifibrinolytic agents
should be reserved for patients who do not tolerate anabolic
androgens or for cases in which anabolic androgens are
contraindicated. In severe cases for which the maximum
dose of androgen is not sufficient to control the attacks,
antifibrinolytic agents can be used in combination with
androgens.
Long-term prophylaxis of HAE is satisfactory for most
patients but has the disadvantage of requiring daily
medication. In some patients, the use of androgens or
antifibrinolytic agents is impractical because of the adverse
reactions that they provoke (principally in females) or
because of a lack of response. In addition, neither class of
drugs is safe for use during pregnancy.
Although they are still unavailable in Brazil, C1-INH
concentrates, which have a grade B recommendation, have
been used elsewhere for the long-term prophylaxis of
HAE.
73-75 Administered intravenously at regular intervals,
approximately three times per week, C1-INH concentrates
constitute a viable therapeutic alternative for individuals in
whom other therapies cannot be used or are ineffective.
Regardless of the drug chosen, the effectiveness of each
drug depends on treatment adherence, which must be
encouraged and evaluated.
How should short-term prophylaxis be performed?
Short-term prophylaxis is indicated for patients under-
going major surgical procedures (e.g., surgery with oro-
tracheal intubation), other surgical procedures (principally
craniofacial procedures), invasive diagnostic procedures
(e.g., endoscopy), or major dental procedures (all patients
should be informed of the higher risk of attacks during
major dental procedures).
In addition to prophylaxis, patients should remain under
observation for 36 h and should have easy access to rescue
medication.
5
Therapeutic intervention should be performed before
the occurrence of events that can provoke HAE attacks.
Favorable results have been obtained with the use of
attenuated androgens, antifibrinolytic agents, fresh frozen
plasma, and C1-INH concentrates (Table 6).
Fresh frozen plasma can be administered intravenously at
a dose of 2 U the night before surgery or on the day of
surgery (grade D recommendation). Epsilon-aminocaproic
acid is effective when it is administered several days before
the triggering event (grade C recommendation). Androgens,
which have a grade C recommendation, are used three-five
days before surgery at doses of 10 mg N kg
21 N day
21, with a
maximum dose of 600 mg/day.
76 For prophylaxis in adults
and children, C1-INH concentrates are safe and effective at
doses of 500-1,000 U when administered intravenously
(grade C recommendation). Some of these products have
also been tested and are currently used in pregnant women.
Initially, in the 1970s, C1-INH concentrate was established
as the emergency treatment for HAE. With the introduction
of viral inactivation processes, C1-INH concentrate also
became a first-line drug for the prophylaxis of acute HAE
attacks. There are two C1-INH concentrates currently in use
in the United States: CinryzeH and BerinertH. Because of
regulatory issues, CinryzeH is indicated for short-term
prophylaxis of HAE but not for the treatment of attacks,
and BerinertH is indicated for the treatment of acute HAE
attacks.
How should HAE attacks be treated?
The treatment of acute HAE attacks depends on their
severity (Table 7). Severe attacks and attacks involving the
respiratory tract require urgent treatment because of the
potential for morbidity and mortality.
Although episodes of peripheral edema rarely require
treatment, the early administration of danazol can shorten
the duration of attacks and uncomfortable symptoms (grade
D recommendation). Patients who are taking attenuated
androgens prophylactically should double the dose for a
few days after identifying an attack in any part of the
body.
76 Therapy with antifibrinolytic agents, such as
tranexamic acid administered orally every 3-4 h, has also
been recommended for mild crisis periods (grade C
recommendation).
Abdominal attacks are extremely painful and can be
accompanied by vomiting, diarrhea, or both. When patients
present with severe abdominal attacks, symptomatic treat-
ment with the administration of fluids, antiemetics, and
analgesics is indicated. Antispasmodics and narcotics may
be required to treat intense pain.
37
Dysphonia and dysphagia are indicative of progression to
a severe laryngeal attack. Such attacks develop slowly over
the course of approximately 8 h on average, and dysphagia
and voice changes generally precede laryngeal obstruc-
tion.
16 However, there have been reports of rapid-onset
laryngeal edema, and physicians should bear this in mind
when evaluating such patients.
More severe cases require immediate intubation. In such
cases, oxygen therapy is indicated, and pulse oximetry
should be monitored. During laryngoscopy and intubation,
the need for tracheostomy should be evaluated.
77 In cases of
laryngeal edema, it may be prudent to perform prophylactic
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and avoid tracheostomy (grade D recommendation).
77
In cases of severe acute attacks, the treatment of choice is
C1-INH replacement therapy, which can be achieved by the
intravenous infusion of 1,000 U of a C1-INH concentrate
(grade A recommendation), by the infusion of recombinant
C1-INH, or, as reported recently, by a kallikrein inhibitor or
a BDKRB2 antagonist (grade B recommendation).
In countries where the aforementioned drugs are not
available, fresh plasma or solvent/detergent-treated plasma,
which contains C1-INH, can be used (grade D recommenda-
tion).However,thistypeoftreatmentcan worsenHAEattacks
because fresh plasma also contains the remaining comple-
ment, coagulation, and contact system components. In
addition, there are concerns regarding the safety of fresh
plasma (e.g., transfusion-related acute lung injury, anaphy-
laxis, and viral transmission), and the need for a relatively
large volume of plasma might be problematic in an emergency
setting or in patients who cannot tolerate significant volume
expansion. Therefore, when C1-INH concentrate, or bradyki-
nin receptor antagonist, or kallikrein inhibitor are available,
they are preferred over plasma transfusion.
37,78,79
The symptoms generally improve 30-40 min after the
infusion of C1-INH concentrate. A second, identical, dose
can be administered if necessary.
The fractional catabolic rate of C1-INH is 2.5% of the
plasma pool per hour. However, in patients with HAE, the
half-life of C1-INH is longer than predicted by the fractional
catabolic rate (.48 h vs. 28 h). This difference is probably
attributable to the observation that exogenous C1-INH
reduces the consumption of endogenous C1-INH, prevent-
ing C1 autoactivation.
50,79,80
RhucinH, which was developed recently, is a recombinant
C1-INH derived from the milk of transgenic rabbits.
75
Although its half-life is only 3 h, RhucinH has been shown to
produce a response similar to that produced by other
commercially available C1-INH preparations in the treat-
ment of HAE attacks (grade B recommendation).
75,81
Further studies are needed to assess the effects of Rhucin.
In addition to C1-INH replacement therapy, blocking the
synthesis and effects of bradykinin constitute other phar-
macological approaches to HAE attacks. Recent studies
have confirmed the efficacy of a kallikrein inhibitor and a
BDKRB2 antagonist.
The BDKRB2 antagonist, icatibant, is highly specific for
BDKRB2, binding to it with the same affinity as bradykinin
and inhibiting a variety of BDKRB2-mediated effects.
82 The
drug is administered subcutaneously, and its plasma half-
life is 2-4 h. Icatibant is degraded by peptidases, and the
products of icatibant degradation are excreted by the
Table 6 - Drugs used for the short-term prophylaxis and treatment of acute attacks of hereditary angioedema.
Short-term prophylaxis Trade name Dose Adverse events
Tranexamic acid TransaminH
HemoblockH
1 g administered orally every 4 h (or
0.5 g administered intravenously
every 4 h) for 18 h
Diarrhea
High-dose attenuated androgens Danazol
Oxandrolone
10 mg N kg
21 N day
21 with a maximum
dose of 600 mg/day for 3-5 days
before the procedure
Weight gain, voice changes,
increased hair growth, and
menstrual irregularity
C1-INH concentrate* and recombinant
C1-INH*
BerinertH
CinryzeH
500-1,000 U on the day before the
procedure or on the day of the
procedure
-
Fresh plasma - 10 ml/kg Hyperosmolarity
Treatment of acute attacks
C1-INH concentrate* and recombinant
C1-INH*
BerinertH
CinryzeH
1,000 U administered intravenously or
10-20 U/kg
-
Fresh plasma - 10 ml/kg Hyperosmolarity
Bradykinin receptor Antagonist Icatibant (FirazyrH) 30 mg/dose and repeat an initial dose
and a second dose if the attack
persists
Local hyperemia
Kallikrein inhibitor* Ecallantide (KalbitorH) 20 U/kg or 30 mg/dose and repeat the
second dose if the attack persists
Hypersensitivity reactions
*Drugs that have not yet been approved in Brazil.
Table 7 - Parameters for the treatment of acute attacks in patients with hereditary angioedema.
6,38
Treatment Edema of the skin Abdominal attack Laryngeal edema
Torso and extremities Face and neck region
Wait and see (spontaneous resolution) ¡ 22 2
Tranexamic acid ++ + +
C1-INH concentrate,
bradykinin receptor antagonist,
kallikrein inhibitor
¡ ++ +
ICU (intubation/tracheostomy) 22 2 +
C1-INH: C1 inhibitor, ICU: intensive care unit.
+ indicated.
¡ consider indication.
2 contraindicated.
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1633kidneys. Icatibant was initially shown to be effective in
treating seasonal allergic rhinitis and asthma. Subsequently,
two double-blind, randomized, multicenter trials (the For
Angioedema Subcutaneous Treatment trial, parts 1 and 2)
found that a single dose of icatibant was effective in 90% of
the attacks of HAE (grade B recommendation).
83 One
perspective that merits investigation is the home treatment
of HAE attacks with icatibant. Icatibant has been approved
in Brazil, and its use is indicated for the treatment of HAE
attacks. Although the drug can be stored at room tempera-
ture, in Brazil, it is suggested that the drug be stored at 4˚C.
Ecallantide is a high-potency recombinant protease
inhibitor that binds to and inhibits kallikrein, thus decreas-
ing bradykinin production. Because of its short half-life
when it is administered subcutaneously, ecallantide has
been evaluated for use in acute HAE attacks only.
Multicenter phase III clinical trials have found a significant
reduction in the severity of acute attacks after ecallantide
administration compared to a placebo (grade B recommen-
dation).
84 Side effects were rare and included dyspnea,
oropharyngeal edema, and prolonged prothrombin and
thrombin times. There have also been isolated reports of
anaphylactic reactions following ecallantide administration;
therefore, the use of the drug is restricted to hospital
environments.
85
To date, no studies been conducted to compare the
efficacy of C1-INH concentrate, icatibant, and ecallantide in
the treatment of HAE attacks.
86
Regarding pharmacological treatment, it should be high-
lighted that, unlike anaphylaxis and edemas associated with
the degranulation of mast cells and basophils, C1-INH
deficiency-induced angioedema does not respond signifi-
cantly to the administration of antihistamines, glucocorti-
coids, or epinephrine.
77
SPECIAL SITUATIONS
Pediatric patients
In pediatric patients, antifibrinolytic agents are the drugs
of choice for long-term prophylaxis because of their safety
profiles (grade C recommendation). Studies have reported
that tranexamic acid is better tolerated than epsilon-
aminocaproic acid. When these agents are not sufficient,
attenuated androgens may be required. The use of
minimum maintenance doses for control has been found
to have no negative impact on growth, and the only adverse
effect that was observed was late menarche with subsequent
menstrual irregularity, which was attributed to the use of
danazol (200 mg/day).
87
During the first two years of prophylaxis, it is recom-
mended that laboratory tests be performed every three-four
months and that abdominal ultrasounds be performed
every six months. The clinical course of HAE should be
monitored, as should any adverse effects of treatment.
Pregnancy and delivery
During pregnancy and, if possible, even before concep-
tion, the ideal situation is that no prophylactic drug be used.
Attenuated androgens are contraindicated, and tranexamic
acid can be used if it is administered with caution (grade C
recommendation).
The treatment of HAE attacks does not change during
pregnancy. Attacks during vaginal delivery are rare.
However, when they do occur, they are severe. Regional
analgesia is recommended for surgical delivery; general
anesthesia and orotracheal intubation should be avoided
(grade C recommendation).
Suspected cases of acute abdomen
Some HAE attacks mimic acute surgical abdomen, and
negative exploratory laparotomy results are common in
such patients.
20,21 However, a diagnosis of HAE raises the
concern that if there is a true abdominal emergency
requiring surgery, the timing of the surgical procedure
may be delayed.
CONCLUSION
The Experts in Clinical Immunology and Allergy of
the ‘‘Associac ¸a ˜o Brasileira de Alergia e Imunopatologia -
ASBAI’’ developed these guidelines for the diagnosis,
therapy, and management of hereditary angioedema. We
hope that these guidelines will aid readers in the diagnosis
and treatment of HAE, which is a neglected disease. A
Portuguese version of this consensus is published in the
‘‘Revista Brasileira de Alergia e Imunopatologia’’.
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